Formation of a Gemcitabine (dFdC) Acquired Resistant BT 549 Triple Negative Breast Cancer Cells
Department of Chemical Pathology, Faculty of Basic Medical Sciences, College of Health Science, Niger Delta University, Bayelsa State, Nigeria.\
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2024, 20(01), 289–295.
Article DOI: 10.30574/wjbphs.2024.20.1.0744
Publication history:
Received on 30 August 2024; revised on 10 October 2024; accepted on 12 October 2024
Abstract:
Triple negative breast cancer (TNBC) is an aggressive variant of breast cancer (BC). TNBC can develop an acquired resistance after repeated exposure to anticancer drugs, which remains a major hurdle for the success of chemotherapy. The relapsed TNBC is commonly pan-resistant to various drugs with completely different resistant mechanisms. Gemcitabine BT549 cells were developed from white-type cells. The acquired resistant cells were observed to show high resistance to Gemcitabine, in addition they were also found to be cross resistant to 3 anticancer drugs (Vincristine, Doxorubicin and Paclitaxel). These acquired resistant cell can be used as models to further study the various mechanisms of resistance in cancer cells.
Keywords:
BT 549 cells; Acquired resistance; Chemotherapy; Cancer cells
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0